{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~68 mi. (Uzhgorod, Ukraine, +192 more cities)
facility
Uzhgorod Central City Clinical Hospital
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~68 mi. (Uzhgorod, Ukraine, +262 more cities)
facility
Uzhgorod Central City Clinical Hospital
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
city
~68 mi. (Uzhgorod, Ukraine, +186 more cities)
facility
Uzhhorod Central City Clinical Hospital
biomarker
ER Positive, +3 more biomarkers
drug
fulvestrant, +2 more drugs
drug type
hormone therapy, +1 more type
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~90 mi. (Nyíregyháza, Hungary, +201 more cities)
facility
Szabolcs-Szatmar-Bereg Megyei Korhazak & Egyetemi Oktatokorhaz /ID# 221704
drug
azacitidine, +1 more drug
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~90 mi. (Nyíregyháza, Hungary, +197 more cities)
facility
Szabolcs-Szatmar-Bereg Megyei Korhazak & Egyetemi Oktatokorhaz /ID# 214425
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
drug
azacitidine, +1 more drug
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
city
~90 mi. (Nyíregyháza, Hungary, +189 more cities)
facility
Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz Josa Andras Okta /ID# 220946
biomarker
del(11)(q10), +27 more biomarkers
drug
navitoclax, +1 more drug
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
city
~90 mi. (Nyíregyháza, Hungary, +72 more cities)
facility
Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház
biomarker
del(11)(q10), +27 more biomarkers
condition
Primary Myelofibrosis, +1 more condition